“The dark clouds of potential US stock delisting looming large” for several major Chinese biotech companies, Scrip recently reported. The April 26 piece, titled “BeiGene, Zai Lab Look To Clear US Delisting Uncertainties,” reviews actions being taken to satisfy disclosure and transparency regulations enacted under the Holding Foreign Companies Accountable Act (HFCAA). Insights from life sciences partner Eric Wu (Shanghai) are included in the article.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.